Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is proud to announce the creation of a purpose built digital surgery and robotics innovation centre, based in Munich, Germany.
The new innovation centre will bring healthcare professionals from Europe, Middle East and Africa together with Smith+Nephew’s R&D and medical education teams to explore digital surgery and robotics techniques and technologies. At the heart of this will be Real Intelligence, Smith+Nephew’s digital ecosystem, including the new state-of-the-art robotics-assisted surgical system CORI◊.
The centre will feature a dedicated medical education facility, where surgeons can refine techniques and experience the latest technology through hands-on learning and immersive simulation technology.
The centre will also home Smith+Nephew’s digital surgery and robotics R+D team, enabling them to collaborate with surgeons, scientists and engineers, driving innovation that meets unmet clinical needs. Many of this team joined Smith+Nephew from Brainlab under the terms of a collaboration agreement announced in 2019.
Smith+Nephew EMEA President, Peter Coenen said, “We are excited to be announcing this state-of-the-art facility focused on the development and delivery of digital surgery technologies and techniques. We look forward to sharing our plans as we progress our technology vision, and to welcoming customers to experience a new approach to medical education when we open next year.”
The new facility, which is expected to open late 2022, will be situated at the Rhythm complex at Kustermann Park, in central Munich. It joins Smith+Nephew’s recently opened robotics R&D and medical education facility in Pittsburgh, US in offering a unique collaborative approach to customer experience and product development.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.